A Randomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2 Diabetic Patients With New York Heart Association Functional Class I or II Heart Failure
Henry J. Dargie, MBChB*,*,
Per R. Hildebrandt, MD
,
Günter A.J. Riegger, MD
,
John J.V. McMurray, MD*,
Stephen O. McMorn, PhD
,
Jeremy N. Roberts, MSc||,
Andrew Zambanini, MRCP
and
John P.H. Wilding, DM¶
* Department of Cardiology, Western Infirmary, Glasgow, Scotland
Department of Cardiology, Frederiksberg Hospital, Fredriksberg, Denmark
Department of Cardiology, University of Regensberg, Regensberg, Germany
Cardiovascular and Metabolic Medicines Development Centre, GlaxoSmithKline, Harlow, England
|| Biomedical Data Sciences, GlaxoSmithKline, Oakville, Canada
¶ Clinical Sciences Centre, University Hospital Aintree, Liverpool, England.

View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Mean BNP Concentrations at Baseline and at Week 52 in Both Treatment Groups (ITT Population)
*Geometric mean ± SE. Data were log-transformed, and then mean and mean ± SE were exponentiated to original scale. Open bars = rosiglitazone (n= 71); solid bars = placebo (n = 74). BNP = brain natriuretic peptide; ITT = intent-to-treat.
|
|

View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Adjudicated Events of Edema and Dyspnea Occurring With or Without Worsening CHF
Open bars = patients with adjudicated event of edema or dyspnea occurring without a concomitant event of definite or possible worsening of chronic heart failure (CHF); solid bars = patients with adjudicated event of edema or dyspnea occurring with a concomitant event of definite or possible worsening of CHF. PLB = placebo; RSG = rosiglitazone.
|
|
Copyright © 2007 by the American College of Cardiology Foundation.